Market Intelligence, Clinical Progress, and High-Purity Reagents for Macrophage-Targeted Therapy Development
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CSF1R drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CSF1R ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CSF1R Products |
| Gene Delivery | CSF1R Promise-ORF / Lentivirus Full-length receptor for stable cell line construction. Ideal for binding/internalization assays. |
View CSF1R Products |
| Benchmark Ab | Anti-CSF1R (Reference Sequence) Recombinant positive control for flow cytometry and blocking assays. |
View CSF1R Products |
| Validator | CSF1R siRNA Set For knockdown verification and specificity controls. |
View CSF1R Products |
| Related Target: CSF1 | CSF1 (M-CSF) Ligand Synergistic pathway component. Essential for functional cell-based assays. |
View CSF1 Products |
| Related Target: IL34 | IL34 Alternative Ligand Distinct binding profile from CSF1. Critical for selectivity studies. |
View IL34 Products |
| Counter Target: KIT | KIT (CD117) Kinase Domain Safety counter-screening. CSF1R inhibitors often show KIT cross-reactivity. |
View KIT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity Profiling (vs FLT3/KIT/PDGFR) | CSF1R Wild-Type and Mutant Kinase Domains available with >95% purity, ATP-competition ready |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno CSF1R ECD ortholog proteins with verified sequence identity for bridging studies |
| Internalization Efficiency (ADC Development) | Full-length CSF1R Lentivirus for stable HEK293/CHO cell lines preserving native conformation and trafficking |
| Ligand Competition (CSF1 vs IL34) | Dual-ligand binding assays enabled by high-purity CSF1 and IL34 reference proteins |
| False Positives / Specificity Controls | Validated siRNA and CRISPR-compatible lentivirus for knockout validation |
Live CSF1R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CSF1R therapeutic space is maturing beyond first-generation kinase inhibitors toward sophisticated macrophage-modulating strategies. With Pexidartinib (Turalio) established for TGCT and emerging applications in Alzheimer's microglial modulation, the competitive landscape is bifurcating between oncology (TAM depletion) and neurodegeneration (microglia reprogramming).
As first-generation small molecules face safety limitations (hepatotoxicity, bone toxicity via osteoclast inhibition), next-wave R&D prioritizes:
- Brain-penetrant selective inhibitors for glioma and neurodegeneration
- Antibody-based modalities (ADCs, bispecifics) to circumvent systemic kinase toxicity
- Combination regimens with checkpoint inhibitors or chemotherapy
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Daiichi Sankyo, Plexium, Novartis | TGCT, Glioma, Solid Tumors | Kinase Selectivity Panel (Need WT + Resistance Mutants) |
| ADC (Antibody-Drug Conjugate) | BioNTech, Synaffix collaborations | CSF1R+ Tumors, TAM-targeted payload delivery | Internalization Assay (Need Full-length Lentivirus Cell Lines) |
| Bispecific (CSF1R x Checkpoint) | Emerging biotech pipeline | Immunotherapy combinations | Heterodimer Validation (Need Cross-reactive ECD proteins) |
| Monoclonal Antibody | Amgen, Bristol Myers Squibb | Rheumatoid Arthritis, Oncology | Ligand Blockade Confirmation (Need CSF1/IL34 competition assays) |